AB-CHMINACA (N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide) is a drug that acts as a potent agonist for the cannabinoid receptorswhich produces subjective effects somewhat similar to that of cannabis. It was developed by Pfizer and disclosed in a 2009 patent as a potential analgesic medication, but was never pursued for human use. It was first found in US customs seizures in February 2014 as a shipment of a kilogram of the chemical originating from China, and detected in herbal blends from March 2014.
Unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects and toxicity in general. Therefore, it is strongly discouraged to take this substance for extended periods of time or in excessive doses.
AB-CHMINACA, or N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide, is a synthetic indazole cannabinoid drug as it contains a substituted indazole core. A cyclohexylmethyl group is bound to this indazole core at R1 of the indazole. This indazole is substituted at R3 with a carboxamide group. The terminal amine of this carboxamide is bonded to a substituted propyl chain with an aminocarbonyl group at R1 and a methyl group at R2.
AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor (Ki = 0.78 nM) and CB2 receptor(Ki = 0.45 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent. Continuing the trend seen in other cannabinoids of this generation, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue.
Top Cannabinoids Shop is a worldwide leader since 2008 in the distribution of Research Chemicals as well as an international research chemicals manufacturing company. We work along side a highly professional laboratory mainly creating custom synthesis, research, and pharmaceutical chemicals.